| abstract |
The present invention relates to a multiple-phase pharmaceutical preparation consisting of a number of separately packaged and individually removable daily dosage units placed in a packaging unit and intended for oral administration for a period of at least 21 consecutive days, wherein said daily dosage unit comprises a natural estrogen, such as estradiol in an amount of from 0.5 mg to 4 mg, and 2 to 4 mg of drospirenone, and wherein at least 70% of said drospirenone is dissolved from said dosage unit within 30 minutes, as determined by USP XXIII Paddle Method II using water at 37°C as the dissolution media and 50 rpm as the stirring rate. |